Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 80, Issue 2, 2008, Pages 299-304

  Zanatta, Claudete M ^a   Gerchman, Fernando ^a   Burttet, Lucas ^a   Nabinger, Gustavo ^a   Jacques Silva, Maria C ^a   Canani, Luís H ^a   Gross, Jorge L ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Diabetes mellitus; Diabetic nephropathy; Endothelial dysfunction; Endothelin; Microalbuminuria

Indexed keywords

ALBUMIN; ENDOTHELIN 1; HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; DISEASE DURATION; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; EVALUATION; FEMALE; HOMEOSTASIS; HUMAN; INSULIN SENSITIVITY; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; SEX DIFFERENCE;

AGE OF ONSET; AGED; ALBUMINURIA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 41749086422     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.12.024     Document Type: Article

References (35)

1. Adler A.I., Stevens R.J., Manley S.E., et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63 (2003) 225-232
2. Nelson R.G., Pettitt D.J., Carraher M.J., et al. Effect of proteinuria on mortality in NIDDM. Diabetes 37 (1988) 1499-1504
3. Marshall S.M. Recent advances in diabetic nephropathy. Postgrad. Med. J. 80 (2004) 624-633
4. Molitch M.E., DeFronzo R.A., Franz M.J., et al. Nephropathy in diabetes. Diab. Care 27 Suppl 1 (2004) S79-S83
5. Parving H.H., Oxenboll B., Svendsen P.A., et al. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol. (Copenh) 100 (1982) 550-555
6. Viberti G.C., Hill R.D., Jarrett R.J., et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1 (1982) 1430-1432
7. Mogensen C.E., and Christensen C.K. Predicting diabetic nephropathy in insulin-dependent patients. N. Engl. J. Med. 311 (1984) 89-93
8. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 310 (1984) 356-360
9. Forsblom C.M., Groop P.H., Ekstrand A., et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diab. Care 21 (1998) 1932-1938
10. Gall M.A., Hougaard P., Borch-Johnsen K., and Parving H.H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 314 (1997) 783-788
11. Murussi M., Baglio P., Gross J.L., and Silveiro S.P. Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study. Diab. Care 25 (2002) 1101-1103
12. Klausen K., Borch-Johnsen K., Feldt-Rasmussen B., et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110 (2004) 32-35
13. Stehouwer C.D., Gall M.A., Twisk J.W., et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51 (2002) 1157-1165
14. Hopfner R.L., and Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia 42 (1999) 1383-1394
15. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139 (2003) 137-147
16. Hocher B., Schwarz A., Reinbacher D., et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 87 (2001) 161-169
17. Sorokin A., and Kohan D.E. Physiology and pathology of endothelin-1 in renal mesangium. Am. J. Physiol. Ren. Physiol. 285 (2003) F579-F589
18. Gomez-Garre D., Ruiz-Ortega M., Ortego M., et al. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 27 (1996) 885-892
19. Seligman B.G., Biolo A., Polanczyk C.A., et al. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diab. Care 23 (2000) 1395-1400
20. Schneider J.G., Tilly N., Hierl T., et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am. J. Hypertens. 15 (2002) 967-972
21. De Mattia G., Cassone-Faldetta M., Bellini C., et al. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am. J. Hypertens. 11 (1998) 983-988
22. Bruno C.M., Meli S., Marcinno M., et al. Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients. J. Biol. Regul. Homeost. Agents 16 (2002) 114-117
23. Vermes I., Spooren P.F., Kalsbeek-Batenburg E.M., and Haanen C. In addition to von Willebrand factor and urinary albumin excretion, plasma endothelin is an indicator of endothelial dysfunction in diabetes mellitus. Diabetologia 36 (1993) 472-473
24. Cosenzi A., Bernobich E., Trevisan R., et al. Nephroprotective effect of bosentan in diabetic rats. J. Cardiovasc. Pharmacol. 42 (2003) 752-756
25. Ding S.S., Qiu C., Hess P., et al. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J. Cardiovasc. Pharmacol. 42 (2003) 48-54
26. Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 727 (1985) 1-113.
27. Bonora E., Targher G., Alberiche M., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diab. Care 23 (2000) 57-63
28. Junge W., Wilke B., Halabi A., and Klein G. Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe's method. Clin. Chim. Acta 344 (2004) 137-148
29. Park J.Y., Takahara N., Gabriele A., et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 49 (2000) 1239-1248
30. Diamanti-Kandarakis E., Spina G., Kouli C., and Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol. Metab. 86 (2001) 4666-4673
31. Drakopoulos A., Goumenos D.S., Vlachojannis J.G., and Tsakas S. Endothelin receptors in the kidney of patients with proteinuric and non-proteinuric nephropathies. Ren. Fail 28 (2006) 461-467
32. Lariviere R., Lebel M., Kingma I., et al. Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am. J. Hypertens. 11 (1998) 989-997
33. Cardillo C., Campia U., Kilcoyne C.M., et al. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation 105 (2002) 452-456
34. Ikeda M., Kohno M., and Takeda T. Endothelin production in cultured mesangial cells of spontaneously hypertensive rats. Hypertension 25 (1995) 1196-1201
35. Schrijvers B.F., De Vriese A.S., and Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr. Rev. 25 (2004) 971-1010